

View and download all Ad Alerts at www.asa.org.uk

Ad Alert

The Copy Advice team
Tel: 020 7492 2100

Email: Submit a query directly to the team through the

online form.

Committee of Advertising Practice Mid City Place, 71 High Holborn London WC1V 6QT

Telephone 020 7492 2200 Textphone 020 7242 8159

No: 759

Date: 25 March 2019

Category: General

Sent to: Direct Marketing, Magazine, National/Regional Press

ADVERTISING OF BOTOX AND OTHER PRESCRIPTION-ONLY MEDICINES

Action: Botox and other prescription-only medicines should not be advertised to the public. Please consult Copy Advice before accepting ads for what you suspect might be prescription-only medicines

This is a reissue of an Ad Alert first published in December 2007 and last updated in December 2017.

The CAP Compliance team remains concerned by the continuing appearance of ads that offer, refer to or allude to prescription-only medicines. Most of the problems still refer to Botox, and to a lesser degree Viagra, but you should also look out for the following: Cialis, Finasteride, Minoxidil (prescription-strength; >5%), Sildenafil, Dysport, Vistabel, Propecia, Xenical, Lignocaine, Lidocaine, Saxenda, Methadone, Avodart, Acomplia and Levitra.

Rule 12.12 of the CAP Code states: "prescription-only medicines or prescription-only medical treatments may not be advertised to the public".

There are three categories in the health and beauty sector that are most commonly associated with the problematic advertising of POMs: cosmetic treatments (injectables), hair replacement programmes and impotence or erectile dysfunction products. It is not always obvious from an ad whether a product is a medicine or whether a treatment programme involves the use of medicines, but trademarked or copyrighted names often give a clue that a medicine is being used.

Note – this Alert does not apply to "Viagra Connect", which was re-classified from a prescription-only medicine (POM) to a pharmacy medicine (P) in November 2017. Other Viagra products, and "Viagra" generally, remain POMs and covered by this Alert.

We would be grateful for your cooperation to ensure that ads for POMs are not placed.

Please consult the CAP Copy Advice team if you are unsure about ads or the Code's requirements.